Praxis Precision Medicines (PRAX) vs Spyre Therapeutics (SYRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Praxis Precision Medicines (PRAX) has outperformed Spyre Therapeutics (SYRE) over the past year, gaining 385.4% versus a gain of 304.8%. Over five years, PRAX leads with a -12.2% price change compared with -58.1% for SYRE. Spyre Therapeutics is the larger company by market cap ($7.91 billion vs $7.26 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRAX | SYRE |
|---|---|---|
| Share price | $259.86 | $85.69 |
| Market cap | $7.26B | $7.91B |
| 1-day change | -1.40% | +7.25% |
| YTD return | -10.58% | +161.57% |
| 1-year return | +385.45% | +304.77% |
| 5-year return | -12.19% | -58.10% |
| EPS (TTM) | $-12.78 | $-2.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $0 |
| Revenue growth (YoY) | -100.00% | — |
| Net income (latest FY) | $-303.27M | $-155.20M |
| 52-week high | $392.70 | $110.18 |
| 52-week low | $50.56 | $18.12 |
| Distance from 52-week high | -33.83% | -22.22% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +147.99% | +40.28% |
| Average volume | 408.88K | 1.22M |
| Shares outstanding | 27.92M | 92.29M |
| Employees | 168 | 125 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRAX has outperformed SYRE by 80.7 percentage points over the past year.
About Praxis Precision Medicines
PRAX stock →Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide.
Health Care · Biotechnology: Pharmaceutical Preparations · 168 employees
About Spyre Therapeutics
SYRE stock →Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A).
Health Care · Biotechnology: Pharmaceutical Preparations · 125 employees
PRAX vs SYRE FAQ
Which is bigger, Praxis Precision Medicines or Spyre Therapeutics?
Spyre Therapeutics (SYRE) is larger, with a market capitalization of $7.91B compared with $7.26B for Praxis Precision Medicines (PRAX).
Which stock has performed better over the past year, PRAX or SYRE?
PRAX returned +385.45% over the past 12 months, compared with +304.77% for SYRE (price return, excluding dividends). Past performance does not predict future results.
Are Praxis Precision Medicines and Spyre Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.